🔍HER2 PARADIGM Trial now enrolling
🔹HER2-0 and HER2-0+ pts with MBC
🔹s/p 1 line of therapy
➡️T-DXd until progression
🎯 HER2 & TROP2 Quantitative immunofluorescence on biopsy sample
NCT06750484
Love working with this outstanding
Yale Breast & @yalepathology.bsky.social team!
@yalecancer.bsky.social

📣lidERA trial📣
🔸Pts with HR+ eBC high/medium risk ➡️ giredestrant vs SOC ET x 5 years
🔸At 32 m, iDFS events 6.7% vs 9.4%, HR 0.7, p=.0014
🔸Arthralgias similar
📍1st trial to report benefit of SERD in the adjuvant tx
📋Looking forward to further data & other trials including CDK4/6i & SERDs💊
#SABCS25

🚨HER2CLIMB05 🚨
🔹Pts HER2+ MBC s/p THP x 4-8 cycles ➡️ HP + tucatinib vs HP
🔹PFS 24.9m vs 16.3m p<.0001
🔹HR- 24.9m vs 12.6m
🔹HR+ 25m vs 18m
⚠️ Increase in diarrhea and hepatic AEs
🔹Control arm had inferior PFS when compared to DB-09 control arm
#SABCS25 #bcsm

📌Starting #SABCS25 off with a discussion of the Advanced Breast Cancer (ABC) Global Decade Report 📈
🔸improved 5 year OS 26% ➡️33%
🔸improvement in QOL, but 79% report negative QOL
🔸access to care gaps have widened
✅ 10 goals 2025-2035
#bcsm @maryamlustberg.bsky.social

💡Phenomenal @onclive.bsky.social Fellows Forum ahead of #SABCS25 presenting important research, learning about advancing our careers, and making connections with the future leaders in breast oncology 🤝 thankful for the [email protected] @brianato.bsky.social

📍Thought provoking end to the Lynn Sage Breast Cancer Symposium discussing the goals of de-escalation in low risk, escalation in high risk, and individualized treatment in intermediate risk patients. Thankful for the opportunity to attend!✨#LSBC25 @luriecancer.bsky.social

💡Fabulous first day of the Lynn Sage Breast Cancer Symposium discussing obesity, sustainability, breast reconstruction, pathology, AI in oncology, approaches to management cans so much more ✨Thank you Lynn Sage for the travel award!💐 #LSBC25 @luriecancer.bsky.social

Yale Heme/Onc fellows riding for our patients, families, and cancer research 🧬 at the 15th annual Closer to Free Ride! 🚴🏼‍♀️💨 @ctfride.bsky.social @yalecancer.bsky.social

📍HER2+ T-DXd+P is likely the new 1L SOC but many questions remain in HR+ pts, QOL, & potential maintenance strategies
📍TNBC SG+pembro likely new 1L SOC but we need more therapies for these patients

Amazing talk #ASCO2025 Highlights in MBC @maryamlustberg.bsky.social @yalecancer.bsky.social
📍HR+ multiple targeted agents now available, optimal sequencing remains unclear, we need to study in combinations

🚨Practice changing interim results DESTINY-Breast09 evaluating 1st Line T-DXd + P vs THP in HER2+ MBC
🔹PFS 40.7 m vs 26.9 m!
🔹PFS2 not reached vs 36.5 m
🔹 OS immature
#ASCO2025

Lots of buzz around TBCRC 040 PREDICT-DNA trial presented by Dr. Natasha Hunter 🐝 ➰
➡️ Among pts w/ Stg II-III HER2+ & TNBC receiving NAT ctDNA may be may be a better biomarker than pCR for longterm outcomes 🧬
🔸54% ctDNA <100 ppm after NAT
🔸NPV for residual disease 60%

Inspirational words on positioning yourself for success by these four women physician leaders! Sharing advice with early career women in oncology. Now we have the tools for success🛠️✨#ASCO2025 @maryamlustberg.bsky.social @drgattimays.bsky.social @yalecancer.bsky.social

Outstanding talk by Dr. Ian Krop on antibody drug conjugates in the era of targeted therapies. 🔬So much groundbreaking work has been done and there’s still more work to do in understanding mechanism, mechanisms of resistance, and biomarkers for response📈📌 #ASCO2025

Impressive & practice changing ASCENT-04/KEYNOTE-D19 evaluating sacituzumab go ite an + pembro vs chemo + pembro in 1st Line PDL1+ metastatic TNBC demonstrating PFS 11.2 vs 7.8 months! 🚨Much needed improvement in 1st Line metastatic TNBC #ASCO2025

Great start to #ASCO2025 with Yale Cancer Center and at the @conquercancer.bsky.social
Awards Ceremony🏆 So grateful to have the opportunity to research improved biomarkers for ADC response in patients with HER2-low, HER2-ultralow, and HER2 0 breast cancer 🔬🩺